Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson
Baxter
Mallinckrodt
McKesson

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

BINOSTO Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Binosto, and when can generic versions of Binosto launch?

Binosto is a drug marketed by Ascend Theraps Us and is included in one NDA. There are two patents protecting this drug.

This drug has eleven patent family members in seven countries.

The generic ingredient in BINOSTO is alendronate sodium. There are twenty-five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the alendronate sodium profile page.

Drug patent expirations by year for BINOSTO
Drug Prices for BINOSTO

See drug prices for BINOSTO

Recent Clinical Trials for BINOSTO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wisconsin Partnership ProgramPhase 1
University of Wisconsin, MadisonPhase 1
National Cancer Institute (NCI)Phase 1

See all BINOSTO clinical trials

Pharmacology for BINOSTO
Drug ClassBisphosphonate
Synonyms for BINOSTO
(4-Amino-1-hydroxy-1-phosphonobutyl)phosphonic Acid Monosodium Salt
(4-Amino-1-hydroxybutylidene)bisphosphonic acid monosodium salt
129318-43-0
4-Amino-1-hydroxybutylidine-1,1-bisphosphonate
4988K7X26P
A805927
AB10152
AC1Q1W16
AHBuBP
AHButBP
AKOS015895071
Alend
ALENDRONATE SODIUM
Alendronate sodium anhydrous
Alendronate, Sodium, Trihydrate
Alendronic Acid Monosodium Salt
Alendronic acid sodium salt
Alendronic acid, Sodium aldendronate
Almerol
AN-32438
API0001401
Avalent
BB_SC-02791
BG0020
Bonalon
C4H12NNaO7P2
CAKRAHQRJGUPIG-UHFFFAOYSA-M
CCG-220631
CHEMBL675
EX-101
Fosamac
Fosamax
G-704650
GTH-42
GTH-42J
GTH-42V
GTH-42W
HMS3604I12
HMS3713P04
Hydrogen (4-amino-1-hydroxy-1-phosphonobutyl)phosphonate (Na+)
I06-0478
Indrol
J-005667
KS-1028
L-670452
LS-106423
MER-103
MFCD00868112
MK 217
MK-0217
MK-217
Monosodium (4-Amino-1-hydroxy-1-phosphonobutyl)phosphonate
Monosodium alendronate
NeoBon
Onclast
Osteovan
P,P'-(4-Amino-1-hydroxybutylidene)bis-phosphonic acid monosodium salt
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-, monosodium salt
SC-22170
SCHEMBL328770
sodium (4-amino-1-hydroxy-1-phosphono-butyl)-hydroxy-phosphinate
sodium (4-amino-1-hydroxy-1-phosphonobutyl)-hydroxyphosphinate
sodium (4-azanyl-1-oxidanyl-1-phosphono-butyl)-oxidanyl-phosphinate
Sodium alendronate
sodium alendronate(1-)
sodium hydrogen-4-amino-1-hydroxy-1-phosphonobutylphosphonate
sodium hydrogen(4-amino-1-hydroxy-1-phosphonobutyl)phosphonate
Steovess
Teiroc
UNII-4988K7X26P
Y-8756

US Patents and Regulatory Information for BINOSTO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ascend Theraps Us BINOSTO alendronate sodium TABLET, EFFERVESCENT;ORAL 202344-001 Mar 12, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Ascend Theraps Us BINOSTO alendronate sodium TABLET, EFFERVESCENT;ORAL 202344-001 Mar 12, 2012 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for BINOSTO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1175904 2007C/048 Belgium   Start Trial PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
AstraZeneca
Johnson and Johnson
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.